Table 1. Clinical characteristics in 307 cases of febrile neutropenia.
| Age, mean years ± SD | 40.7±14.2 |
| Female sex | 148 (48.2) |
| Type of cancer | |
| Acute myeloid leukemia | 149 (48.5) |
| Acute lymphoblastic leukemia | 45 (14.6) |
| Chronic myeloid leukemia | 18 (5.8) |
| Multiple myeloma | 30 (9.7) |
| Lymphoma | 51 (16.6) |
| Other solid tumors | 14 (4.5) |
| Relapsing underlying disease | 155 (50.4) |
| Clinical comorbidity | 76 (24.7) |
| Phase of chemotherapy | |
| Induction | 76 (24.7) |
| Consolidation | 86 (28.0) |
| Maintenance | 57 (18.6) |
| HSCT | 88 (28.7) |
| ANC at the time of diagnosis of FN, median cells/mm3 (IQR) | 130 (260) |
| Duration of neutropenia, median days (IQR) | 9 (12) |
| Nosocomial-acquired episodes of FN | 250 (81.7) |
| Bloodstream infection | 115 (37.4) |
| BSI involving Gram-positive bacteria | 46 (14.9) |
| BSI involving Gram-negative bacteria | 74 (24.1) |
| Polymicrobial BSI | 12 (3.9) |
| BSI involving Gram-positive MDR bacteria | 27 (8.7) |
| BSI involving Gram-negative MDR bacteria | 12 (3.9) |
| Proven or probable IFI | 22 (7.1) |
Data presented as n (%) unless otherwise indicated. SD = standard deviation; HSCT = hematopoietic stem cell transplantation; ANC = absolute neutrophil count; FN = febrile neutropenia; IQR = interquartile range (P75–P25); BSI = bloodstream infection; MDR = multi-drug-resistant; IFI = invasive fungal infection.